Literature DB >> 30209215

Autonomous conformational regulation of β3 integrin and the conformation-dependent property of HPA-1a alloantibodies.

Aye Myat Myat Thinn1,2, Zhengli Wang1, Dongwen Zhou1, Yan Zhao1,3, Brian R Curtis1, Jieqing Zhu4,2.   

Abstract

Integrin α/β heterodimer adopts a compact bent conformation in the resting state, and upon activation undergoes a large-scale conformational rearrangement. During the inside-out activation, signals impinging on the cytoplasmic tail of β subunit induce the α/β separation at the transmembrane and cytoplasmic domains, leading to the extended conformation of the ectodomain with the separated leg and the opening headpiece that is required for the high-affinity ligand binding. It remains enigmatic which integrin subunit drives the bent-to-extended conformational rearrangement in the inside-out activation. The β3 integrins, including αIIbβ3 and αVβ3, are the prototypes for understanding integrin structural regulation. The Leu33Pro polymorphism located at the β3 PSI domain defines the human platelet-specific alloantigen (HPA) 1a/b, which provokes the alloimmune response leading to clinically important bleeding disorders. Some, but not all, anti-HPA-1a alloantibodies can distinguish the αIIbβ3 from αVβ3 and affect their functions with unknown mechanisms. Here we designed a single-chain β3 subunit that mimics a separation of α/β heterodimer on inside-out activation. Our crystallographic and functional studies show that the single-chain β3 integrin folds into a bent conformation in solution but spontaneously extends on the cell surface. This demonstrates that the β3 subunit autonomously drives the membrane-dependent conformational rearrangement during integrin activation. Using the single-chain β3 integrin, we identified the conformation-dependent property of anti-HPA-1a alloantibodies, which enables them to differently recognize the β3 in the bent state vs. the extended state and in the complex with αIIb vs. αV This study provides deeper understandings of integrin conformational activation on the cell surface.

Entities:  

Keywords:  alloimmune thrombocytopenia; conformational change; human platelet alloantigen 1; integrin activation; integrin structure

Mesh:

Substances:

Year:  2018        PMID: 30209215      PMCID: PMC6166792          DOI: 10.1073/pnas.1806205115

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  75 in total

1.  Regulation of integrin affinity on cell surfaces.

Authors:  Thomas Schürpf; Timothy A Springer
Journal:  EMBO J       Date:  2011-09-23       Impact factor: 11.598

Review 2.  Integration of actin dynamics and cell adhesion by a three-dimensional, mechanosensitive molecular clutch.

Authors:  Lindsay B Case; Clare M Waterman
Journal:  Nat Cell Biol       Date:  2015-06-29       Impact factor: 28.824

3.  Metal ion and ligand binding of integrin α5β1.

Authors:  Wei Xia; Timothy A Springer
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-04       Impact factor: 11.205

4.  iMOSFLM: a new graphical interface for diffraction-image processing with MOSFLM.

Authors:  T Geoff G Battye; Luke Kontogiannis; Owen Johnson; Harold R Powell; Andrew G W Leslie
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2011-03-18

5.  Features and development of Coot.

Authors:  P Emsley; B Lohkamp; W G Scott; K Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-03-24

6.  The structure of a receptor with two associating transmembrane domains on the cell surface: integrin alphaIIbbeta3.

Authors:  Jieqing Zhu; Bing-Hao Luo; Patrick Barth; Jack Schonbrun; David Baker; Timothy A Springer
Journal:  Mol Cell       Date:  2009-04-24       Impact factor: 17.970

Review 7.  Mechanisms of talin-dependent integrin signaling and crosstalk.

Authors:  Mitali Das; Sujay Ithychanda; Jun Qin; Edward F Plow
Journal:  Biochim Biophys Acta       Date:  2013-07-24

Review 8.  Anti-integrin monoclonal antibodies.

Authors:  Adam Byron; Jonathan D Humphries; Janet A Askari; Sue E Craig; A Paul Mould; Martin J Humphries
Journal:  J Cell Sci       Date:  2009-11-15       Impact factor: 5.285

9.  Complete integrin headpiece opening in eight steps.

Authors:  Jieqing Zhu; Jianghai Zhu; Timothy A Springer
Journal:  J Cell Biol       Date:  2013-06-24       Impact factor: 10.539

Review 10.  Integrin-mediated mechanotransduction.

Authors:  Zhiqi Sun; Shengzhen S Guo; Reinhard Fässler
Journal:  J Cell Biol       Date:  2016-11-08       Impact factor: 10.539

View more
  5 in total

1.  High-resolution mapping of the polyclonal immune response to the human platelet alloantigen HPA-1a (PlA1).

Authors:  Huiying Zhi; Maria Therese Ahlen; Aye Myat Myat Thinn; Hartmut Weiler; Brian R Curtis; Bjørn Skogen; Jieqing Zhu; Peter J Newman
Journal:  Blood Adv       Date:  2018-11-13

Review 2.  Dynamic bonds and their roles in mechanosensing.

Authors:  Cheng Zhu; Yunfeng Chen; Lining Arnold Ju
Journal:  Curr Opin Chem Biol       Date:  2019-09-27       Impact factor: 8.822

3.  Current Anti-HPA-1a Standard Antibodies React with the β3 Integrin Subunit but not with αIIbβ3 and αvβ3 Complexes.

Authors:  Behnaz Bayat; Annalena Traum; Heike Berghöfer; Silke Werth; Jieging Zhu; Gregor Bein; Ulrich J Sachs; Sentot Santoso
Journal:  Thromb Haemost       Date:  2019-10-06       Impact factor: 5.249

4.  Naturally occurring point mutation Cys460Trp located in the I-EGF1 domain of integrin β3 alters the binding of some anti-HPA-1a antibodies.

Authors:  Sarah Theresa Holzwarth; Behnaz Bayat; Jieqing Zhu; Roongaroon Phuangtham; Lars Fischer; Doris Boeckelmann; Lida Röder; Heike Berghöfer; Silke Schmidt; Gregor Bein; Sentot Santoso
Journal:  Transfusion       Date:  2020-08-08       Impact factor: 3.157

5.  An integrin αIIbβ3 intermediate affinity state mediates biomechanical platelet aggregation.

Authors:  Yunfeng Chen; Lining Arnold Ju; Fangyuan Zhou; Jiexi Liao; Lingzhou Xue; Qian Peter Su; Dayong Jin; Yuping Yuan; Hang Lu; Shaun P Jackson; Cheng Zhu
Journal:  Nat Mater       Date:  2019-03-25       Impact factor: 43.841

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.